NLRP3 and cardiomyopathy: It has been proven that the knockout of NLRP3 or IL-1β receptor antagonists improved the mitochondrial structure of muscle fibers and ultimately restored cardiac function of cardiomyopathy via reducing the extracellular matrix (Bracey et al., 2013; Luo et al., 2014).